Amneal Pharmaceuticals, Inc. (AMRX) Guidance & Earnings Results

On 2026-07-30 Amneal Pharmaceuticals, Inc. raised guidance: "Net revenue raised to $3.10B-$3.20B; Adjusted EBITDA raised to $750M-$780M; Adjusted EPS raised to…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

AMRXAmneal Pharmaceuticals, Inc.Follow AMRX — free

Drug Manufacturers - Specialty & Generic · Healthcare

—

Price chart with a free account

Market cap: 6.5B
P/E TTM: 41.6
Dividend yield: —
52-week: —
Next earnings: 3 Nov, in 10 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
30 Jul 26	Raised	Net revenue raised to $3.10B-$3.20B; Adjusted EBITDA raised to $750M-$780M; Adjusted EPS raised to $0.96-$1.06 · full year
7 May 26	Raised	Net revenue $3.05B-$3.15B, adjusted EBITDA $740M-$770M, adjusted diluted EPS $0.95-$1.05 · full year
27 Feb 26	Raised	FY2026 net revenue $3.05B-$3.15B; Adj EBITDA $720M-$760M; Adj diluted EPS $0.93-$1.03 · full year
13 Jan 26	Reaffirmed	FY2025 net revenue $3.0-3.1B; adjusted EBITDA $675-685M; adjusted diluted EPS $0.75-0.80; operating cash flow $300-330M; capex ~$100M · full year
30 Oct 25	Raised	Adjusted EBITDA guidance raised to $675-$685M; adjusted EPS to $0.75-$0.80 · full year
5 Aug 25	Raised	FY2025 adjusted EBITDA raised to $665M-$685M from $650M-$675M; adjusted diluted EPS raised to $0.70-$0.75 from $0.65-$0.70; operating cash flow raised to $275M-$305M from $255M-$285M; net revenue unchanged $3.0B-$3.1B; capex ~$100M · full year

Amneal Pharmaceuticals, Inc. — questions

What guidance did Amneal Pharmaceuticals, Inc. give?: On 2026-07-30: "Net revenue raised to $3.10B-$3.20B; Adjusted EBITDA raised to $750M-$780M; Adjusted EPS raised to $0.96-$1.06"
When does Amneal Pharmaceuticals, Inc. report earnings?: Amneal Pharmaceuticals, Inc.'s next earnings report is expected on 2026-11-03.

Every figure on this page comes from Amneal Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.